tbuckley/cabot-search huggingface dataset:
DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through <i>MAFG</i> Overexpression in Cancer Cells
Authors: Olga Vera, Julia Jimenez, Olga Pernia, Carlos Rodriguez-Antolin, Carmen Rodriguez, Fatima Sanchez Cabo, Javier Soto, Rocio Rosas, Sara Lopez-Magallon, Isabel Esteban Rodriguez, Ana Dopazo, Federico Rojo, Cristobal Belda, Rafael Alvarez, Jaime Valentin, Javier Benitez, Rosario Perona, Javier De Castro, Inmaculada Ibanez de Caceres
Journal: Theranostics (2017)

One of the major limitations associated with platinum use is the resistance that almost invariably develops in different tumor types.In the current study, we sought to identify epigenetically regulated microRNAs as novel biomarkers of platinum resistance in lung and ovarian cancers, the ones with highest ratios of associated chemo-resistance.Methods: We combined transcriptomic data from microRNA and mRNA under the influence of an epigenetic reactivation treatment in a panel of four paired cisplatin -sensitive and -resistant cell lines, followed by real-time expression and epigenetic validations for accurate candidate selection in 19 human cancer cell lines.To identify specific candidate genes under miRNA regulation, we assembled "in silico" miRNAs and mRNAs sequences by using ten different algorithms followed by qRT-PCR validation.Functional assays of site-directed mutagenesis and luciferase activity, miRNAs precursor overexpression, silencing by antago-miR and cell viability were performed to confirm their specificity in gene regulation.Results were further explored in 187 primary samples obtained from ovarian tumors and controls.Results: We identified 4 candidates, miR-7, miR-132, miR-335 and miR-148a, which deregulation seems to be a common event in the development of resistance to cisplatin in both tumor types.miR-7 presented specific methylation in resistant cell lines, and was associated with poorer prognosis in ovarian cancer patients.Our experimental results strongly support the direct regulation of MAFG through miR-7 and their involvement in the development of CDDP resistance in human tumor cells. Conclusion:The basal methylation status of miR-7 before treatment may be a potential clinical epigenetic biomarker, predictor of the chemotherapy outcome to CDDP in ovarian cancer patients.To the best of our knowledge, this is the first report linking the regulation of MAFG by miRNA-7 and its role in chemotherapy response to CDDP.Furthermore, this data highlights the possible role of MAFG as a novel therapeutic target for platinum resistant tumors.
TCT-579 Periprocedural Pulmonary Venous Waveforms Predict Rehospitalization and Mortality after Percutaneous Mitral Valve Repair
Authors: Frank Corrigan, John Chen, John Lisko, Norihiko Kamioka, Shawn Reginauld, Jose Miguel Iturbe, Patricia Keegan, Vinod Thourani, Vasilis Babaliaros
Journal: Journal of the American College of Cardiology (2017)
Allergic eye disease
Authors: Darshak S Patel, Meena Arunakirinathan, Alastair Stuart, Romesh Angunawela
Journal: BMJ (2017)

#### What you need to know

Allergic eye diseases include conjunctivitis and occasionally keratitis in response to an allergen. The diseases affect 10%-20% of people globally12 and have a negative impact on quality of life and productivity.3456

Early diagnosis and appropriate treatment is essential to reduce the frequency of relapses, to avoid complications that are potentially sight threatening, and to enhance patient self care. This article provides guidance on recognising the different forms of allergic eye disease and on their management.

Children and adolescents are more commonly affected by atopic disease in general, which tends to diminish with age. People with asthma, eczema, and rhinitis often experience concurrent ocular allergy.7 Europe, North America, and Japan report higher prevalence than developing countries.1

### How do they present?

Itching is the hallmark of allergic eye disease, which is accompanied by redness and watering of the eyes (fig 1⇓). Symptoms may occur in acute episodes which are generally recurrent or may be persistent in a chronic form.



Fig 1  Seasonal allergic conjunctivitis presenting acutely, with conjunctival redness and swelling (chemosis). Note that the cornea is clear, with no signs of keratitis



### What are the different types of allergic eye disease?

Table 1⇓ summarises the different types.

View this table:

Table 1 
Clinical presentation and features of allergic eye disease subtypes



### Common allergic eye diseases

Seasonal and perennial allergic conjunctivitis are the commonest forms of allergic eye disease and are associated with childhood atopy. Seasonal conjunctivitis is triggered by pollen and frequently occurs in spring and summer. It is often associated with nasal symptoms (rhinoconjunctivitis).

Perennial …
TCT-700 Comparison of the Predictive Performance of Dilemma and P20DAC2 Scoring Systems to Determine the Significance of LAD Intermediate Lesions
Authors: Arzu Kalayci, Ecem Akdogan, Can Karabay, Ibrahim Tanboga, Abdurrahman Naser, Ozkan Candan, Cetin Gecmen, Ender Ozgun Cakmak, Muslum Sahin, Ibrahim Akin Izgi, Mehmet Muhsin Turkmen, Cevat Kirma
Journal: Journal of the American College of Cardiology (2017)
TCT-388 Does ST Segment Elevation in Lead aVR Correlate with Left Main Occlusion?
Authors: Ahmed Harhash, Sridhar Reddy, Jennifer Huang-Tsang, Balaji Natarajan, Mahesh Balakrishnan, Ranjith Shetty, Mathew Hutchinson, Karl Kern
Journal: Journal of the American College of Cardiology (2017)
Sun Protection Policies in Public School Districts With Elementary Schools in California
Authors: Julia Berteletti, David B. Buller, Kim Massie, Jeff Ashley, Xia Liu, Kim D. Reynolds
Journal: JAMA Dermatology (2017)

of scribe usefulness improved over baseline, more strongly agreeing with documentation burden and increased job satisfaction after implementation (Table ).Of 19 respondents, 15 (79%) reported willingness to increase patient volume with scribe support.Overall, there was a 7.7% increase in revenue comparing each physician's scribesupported sessions to unsupported sessions in the last quarters of 2016 to 2015 respectively, which more than off-set the cost of the scribes.Overall, roughly 1 additional patient per session covered the hospital's scribe costs.Discussion | Our scribe pilot program achieved significant documentation time savings and reduction of physician burnout factors.Dermatologists' willingness to see additional patients with scribe support reflected enhanced physician efficiency, improved patient access, and increased clinical revenue.A thirdparty contractor overseeing scribe hiring, training, and management enabled rapid implementation, minimized quality variability, and minimized impedance of physician workflow.Scribes were well received by patients, with few refusals and unchanged overall patient satisfaction scores.Other solutions combatting physician documentation burdens, such as real-time dictation software or conventional transcription services, have been employed particularly successfully in diagnostic specialties, such as pathology and radiology, which have limited point-of-care patient interaction.Conclusions | Scribes enable dermatologists to achieve real-time documentation, thereby improving physician efficiency and freeing time for scholarly, leadership, teaching, or personal pursuits.Our initiative's limitations include its single-institutional nature, though we achieved scalable implementation across multiple practices.Our observation that dermatologists did not report increased time with patients following scribe-support likely reflects
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2
Authors: Patricia A. Ganz, Edward H. Romond, Reena S. Cecchini, Priya Rastogi, Charles E. Geyer, Sandra M. Swain, Jong-Hyeon Jeong, Louis Fehrenbacher, Howard M. Gross, Adam M. Brufsky, Patrick J. Flynn, Tanya A. Wahl, Thomas E. Seay, James L. Wade, David D. Biggs, James N. Atkins, Jonathan Polikoff, John L. Zapas, Eleftherios P. Mamounas, Norman Wolmark
Journal: Journal of Clinical Oncology (2017)

Purpose Early cardiac toxicity is a risk associated with adjuvant chemotherapy plus trastuzumab. However, objective measures of cardiac function and health-related quality of life are lacking in long-term follow-up of patients who remain cancer free after completion of adjuvant treatment. Patients and Methods Patients in NSABP Protocol B-31 received anthracycline and taxane chemotherapy with or without trastuzumab for adjuvant treatment of node-positive, human epidermal growth factor receptor 2-positive early-stage breast cancer. A long-term follow-up assessment was undertaken for patients who were alive and disease free, which included measurement of left ventricular ejection fraction by multigated acquisition scan along with patient-reported outcomes using the Duke Activity Status Index (DASI), the Medical Outcomes Study questionnaire, and a review of current medications and comorbid conditions. Results At a median follow-up of 8.8 years among eligible participants, five (4.5%) of 110 in the control group and 10 (3.4%) of 297 in the trastuzumab group had a > 10% decline in left ventricular ejection fraction from baseline to a value < 50%. Lower DASI scores correlated with age and use of medications for hypertension, cardiac conditions, diabetes, and hyperlipidemia, but not with whether patients had received trastuzumab. Conclusion In patients without underlying cardiac disease at baseline, the addition of trastuzumab to adjuvant anthracycline and taxane-based chemotherapy does not result in long-term worsening of cardiac function, cardiac symptoms, or health-related quality of life. The DASI questionnaire may provide a simple and useful tool for monitoring patient-reported changes that reflect cardiac function.
Evaluation of Military Use of Tranexamic Acid and Associated Thromboembolic Events
Authors: Luke R. Johnston, Carlos J. Rodriguez, Eric A. Elster, Matthew J. Bradley
Journal: JAMA Surgery (2017)

Since publication of the CRASH-2 and MATTERs studies, the US military has included tranexamic acid (TXA) in clinical practice guidelines. While TXA was shown to decrease mortality in trauma patients requiring massive transfusion, improper administration and increased risk of venous thromboembolism remain a concern.To determine the appropriateness of TXA administration by US military medical personnel based on current Joint Trauma System clinical practice guidelines and to determine if TXA administration is associated with venous thromboembolism.This cohort study of US military casualties in US military combat support hospitals in Afghanistan and a single US-based tertiary military treatment facility within the continental United States was conducted from 2011 to 2015, with follow-up through initial hospitalization and readmissions.Data collected for all patients included demographic information as well as Injury Severity Score; receipt of blood products, TXA, and/or a massive transfusion; and admission hemodynamics.Variance from guidelines in TXA administration and venous thromboembolism. Tranexamic acid overuse was defined as a hemodynamically stable patient receiving TXA but not a massive transfusion, underuse was defined as a patient receiving a massive transfusion but not TXA, and TXA administration was considered delayed when given more than 3 hours after injury.Of the 455 identified patients, 443 (97.4%) were male, and the mean (SD) age was 25.3 (4.8) years. A total of 173 patients (38.0%) received a massive transfusion, and 139 (30.5%) received TXA in theater. Overuse occurred in 18 of 282 patients (6.4%) and underuse in 46 of 173 (26.6%) receiving massive transfusions, and delayed administration was found in 6 of 145 patients (4.3%) receiving TXA. Overuse increased at 3.3% per quarter (95% CI, 4.0-9.9; P < .001; R2 = 0.340) and underuse decreased at -4.4% per quarter (95% CI, -4.5 to -3.6; P < .001; R2 = 0.410). Tranexamic acid administration was an independent risk factor for venous thromboembolism (odds ratio, 2.58; 95% CI, 1.20-5.56; P = .02).Military medical personnel decreased missed opportunities to appropriately use TXA but also increased overuse. In addition, TXA administration was an independent risk factor for venous thromboembolism. A reevaluation of the use of TXA in combat casualties should be undertaken.
TCT-370 Comparison of Acute Thrombogenicity for Magnesium vs Stainless Steel Stents in a Porcine Arteriovenous Shunt Model
Authors: Michael Lipinski, Eduardo Acampado, Qi Cheng, Lila Adams, Sho Torii, David Hellinga, Rebecca Torguson, Philine Zumstein, Frank Kolodgie, Renu Virmani, Ron Waksman
Journal: Journal of the American College of Cardiology (2017)
Severity strata for five patient-reported outcomes in adults with atopic dermatitis
Authors: P.P. Vakharia, R. Chopra, R. Sacotte, N. Patel, S. Immaneni, T. White, R. Kantor, D.Y. Hsu, E.L. Simpson, J.I. Silverberg
Journal: British Journal of Dermatology (2017)

Summary Background Several patient-reported outcomes have been used to assess the burden of atopic dermatitis (AD). Some are disease specific, such as the Patient-Oriented Eczema Measure (POEM), while others pertain to itch, for example the numerical rating scale (NRS)-itch, ItchyQoL and 5-D itch, or dermatological disease in general, for example the Dermatology Life Quality Index (DLQI). Development of severity strata is essential for proper interpretability of these assessments. Objectives To confirm previously developed strata for POEM, DLQI and raw ItchyQoL, and develop strata for the NRS-itch, mean ItchyQoL and 5-D itch scale for use in adults with AD. Methods Self-administered questionnaires were completed by 210 adults with AD in a dermatology practice setting. Strata were selected using an anchoring approach based on patient-reported disease severity. Results We confirmed the existing strata for POEM (mild 0–7, moderate 8–16, severe 17–28; κ = 0·440), DLQI (mild 0–5, moderate 6–10, severe 11–30; κ = 0·398) and NRS-itch (mild 0–3, moderate 4–6, severe 7–10; κ = 0·499). However, the preferred band for raw ItchyQoL was mild 22–58, moderate 59–74 and severe 75–110 (κ = 0·379) and for mean ItchyQoL, mild 1–2·9, moderate 3·0–3·9, severe 4·0–5·0 (κ = 0·374). The preferred band for 5-D itch scale was mild 0–11, moderate 12–17 and severe 18–25 (κ = 0·331). Conclusions Existing strata for POEM and DLQI performed well in adult AD. Previously reported strata for visual analogue scale-itch performed best for NRS-itch. We identified banding for the raw ItchyQoL for our AD population that varies slightly from the banding published for a more heterogeneous population. Finally, we proposed strata for mean ItchyQoL and 5-D itch scale in adult AD.
TCT-193 Effect of access site on silent cerebral infarct in patients undergoing coronary angiography and intervention as detected with neuron specific enolase
Authors: Hüseyin Göksülük, Sadi Gulec, Nil Özyüncü, Seda Kürklü, Demet Uludağ, Semih Öztürk, Çetin Erol
Journal: Journal of the American College of Cardiology (2017)
Cost-effectiveness of PCSK9 Inhibitors
Authors: Robert O. Bonow, Robert A. Harrington, Clyde W. Yancy
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
TCT-281 Prognostic Relevance of Left Ventricular Myocardial Performance Following Transcatheter Aortic Valve Replacement
Authors: Masahiko Asami, Thomas Pilgrim, Jonas Lanz, Dik Heg, Raffaele Piccolo, Bettina Langhammer, Fabien Praz, Marco Valgimigli, Eva Roost, Stephan Windecker, Stefan Stortecky
Journal: Journal of the American College of Cardiology (2017)
P1.03-078 Size Matters...but Don't Underestimate the Power of Morphology
Authors: Annemie Snoeckx, Damien Desbuquoit, Maarten Spinhoven, Annelies Janssens, Patrick Lauwers, Michèle De Waele, Christel De Pooter, Patrick Pauwels, Jan Van Meerbeeck, Paul Parizel
Journal: Journal of Thoracic Oncology (2017)
Cardiovascular effects of hydroxychloroquine: a systematic review and meta-analysis
Authors: Sylvain Mathieu, Bruno Pereira, Anne Tournadre, Martin Soubrier
Journal: Annals of the Rheumatic Diseases (2017)

In an article published in the Annals of the Rheumatic Diseases , Rempenault et al 1 suggested that hydroxychloroquine (HCQ) had a beneficial effect on the metabolic profile in patients with rheumatoid arthritis (RA). In this letter, we wish to add further data to support the conclusions of this article. We performed a meta-analysis (up to June 2017) to investigate cardiovascular risk in patients treated with HCQ for RA, lupus and other diseases.

We searched MEDLINE to identify all reports of interest published prior to June 2017 using the following search terms: ‘hydroxychloroquine AND (cardiovascular OR myocardial OR stroke OR atherosclerosis OR lipid OR diabetes OR glycemia)’. We retrieved a total …
Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts
Authors: Christina Magnussen, Teemu J. Niiranen, Francisco M. Ojeda, Francesco Gianfagna, Stefan Blankenberg, Inger Njølstad, Erkki Vartiainen, Susana Sans, Gerard Pasterkamp, Maria Hughes, Simona Costanzo, Maria Benedetta Donati, Pekka Jousilahti, Allan Linneberg, Tarja Palosaari, Giovanni de Gaetano, Martin Bobak, Hester M. den Ruijter, Ellisiv Mathiesen, Torben Jørgensen, Stefan Söderberg, Kari Kuulasmaa, Tanja Zeller, Licia Iacoviello, Veikko Salomaa, Renate B. Schnabel
Journal: Circulation (2017)

Atrial fibrillation (AF) is a common cardiac disease in aging populations with high comorbidity and mortality. Sex differences in AF epidemiology are insufficiently understood.In N=79 793 individuals without AF diagnosis at baseline (median age, 49.6 years; age range, 24.1-97.6 years; 51.7% women) from 4 community-based European studies (FINRISK, DanMONICA, Moli-sani Northern Sweden) of the BiomarCaRE consortium (Biomarker for Cardiovascular Risk Assessment in Europe), we examined AF incidence, its association with mortality, common risk factors, biomarkers, and prevalent cardiovascular disease, and their attributable risk by sex. Median follow-up time was 12.6 (to a maximum of 28.2) years.Fewer AF cases were observed in women (N=1796; 4.4%), than in men (N=2465; 6.4%). Cardiovascular risk factor distribution and lipid profile at baseline were less beneficial in men than in women, and cardiovascular disease was more prevalent in men. Cumulative incidence increased markedly after the age of 50 years in men and after 60 years in women. The lifetime risk was similar (>30%) for both sexes. Subjects with incident AF had a 3.5-fold risk of death in comparison with those without AF. Multivariable-adjusted models showed sex differences for the association of body mass index and AF (hazard ratio per standard deviation increase, 1.18; 95% confidence interval [CI], 1.12-1.23 in women versus 1.31; 95% CI 1.25-1.38 in men; interaction P value of 0.001). Total cholesterol was inversely associated with incident AF with a greater risk reduction in women (hazard ratio per SD, 0.86; 95% CI, 0.81-0.90 versus 0.92; 95% CI, 0.88-0.97 in men; interaction P value of 0.023). No sex differences were seen for C-reactive protein and N-terminal pro B-type natriuretic peptide. The population-attributable risk of all risk factors combined was 41.9% in women and 46.0% in men. About 20% of the risk was observed for body mass index.Lifetime risk of AF was high, and AF was strongly associated with increased mortality both in women and men. Body mass index explained the largest proportion of AF risk. Observed sex differences in the association of body mass index and total cholesterol with AF need to be evaluated for underlying pathophysiology and relevance to sex-specific prevention strategies.
Datos de vigilancia sobre infecciones por VIH y Sida pediátricos en Grecia
Authors: G Nikolopoulos, V Konte, A Masgala, E Eleni, A Tsantes, D Paraskeva
Journal: Eurosurveillance (2004)

En Grecia, la vigilancia del VIH/Sida se lleva a cabo por el Centro Helenico de vigilancia de enfermedades infecciosas. El sistema de notificacion de casos de Sida fue iniciado en 1984, seguido por la notificacion de infecciones por VIH en 1998. Este articulo presenta la vigilancia y el analisis de tendencia de las infecciones por VIH y Sida en ninos, incluyendo los casos identificados antes de 1998. 
El numero de ninos infectados por el VIH en Grecia es relativamente bajo, alcanzando un total acumulado de 69 casos en junio de 2003. El 63.76% de estos casos (44) fueron probablemente infectados por transmision de madre a hijo. Desde la aparicion del brote, se notificaron 33 casos de Sida en ninos, siendo la neumonia por Pneumocystis carinii la infeccion oportunista mas frecuente. 
Un numero significativo de ninos en Grecia fueron diagnosticados con mas de un ano de edad. Esto puede ser atribuido al hecho que muchas mujeres infectadas por el VIH no son identificadas durante su embarazo, aunque se ofrezca la posibilidad de realizar pruebas de anticuerpos de forma voluntaria. Tambien podria ser atribuido al hecho que los datos incluyen infecciones por el VIH recogidas retrospectivamente despues de 1998, y que ninos extranjeros infectados por el VIH pueden haber llegado a Grecia con mas edad. Ademas, los nuevos casos pediatricos de infecciones declaradas durante los primeros seis meses de 2003 eran ninos nacidos en Europa del este y en Africa sub-Sahariana. Es importante esforzarse en identificar a tiempo a las mujeres de estas poblaciones para poder actuar de manera eficaz. La infeccion por VIH en ninos sigue representando un problema esencial a nivel mundial, y debe ser una prioridad reducir el riesgo de transmision de madre a hijo.